查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1855638

PD-1 和 PD-L1 抑制劑市場按產品類型、適應症、最終用戶、分銷管道、給藥途徑和公司分類 - 全球預測 2025-2032 年

PD-1 & PD-L1 Inhibitors Market by Product Type, Indication, End User, Distribution Channel, Route Of Administration, Company - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，PD-1 和 PD-L1 抑制劑市場將成長至 2,080.6 億美元，複合年成長率為 21.22%。

主要市場統計數據
基準年 2024 446.1億美元
預計年份：2025年 539.1億美元
預測年份：2032年 2080.6億美元
複合年成長率 (%) 21.22%

一份關於PD-1和PD-L1抑制劑的策略性入門指南，闡述了其臨床成熟度、競爭優勢以及對腫瘤學相關人員的系統性影響。

免疫查核點抑制劑領域已從概念驗證發展成為現代腫瘤學的基石，這主要得益於標靶PD-1和PD-L1的療法。這些藥物使以往全身性治療選擇有限的患者群體獲得了持久的療效，改變了多種腫瘤的治療模式。因此，生物製藥、腫瘤臨床實踐和政策相關人員正在調整其產品組合、臨床路徑和報銷策略，以適應免疫調節在組合方案和長期疾病控制中發揮核心作用的時代。

科學組合策略、監管靈活性和商業性創新如何融合，從而重新定義免疫查核點療法的治療軌跡

PD-1和PD-L1抑制劑的治療格局正受到科學、監管和商業性因素的共同影響而轉變。從機制上看，該領域正從單藥治療轉向將查核點抑制劑與標靶治療、細胞毒性藥物、抗血管生成藥物以及新型免疫調節劑進行合理聯合治療，以擴大患者獲益並克服抗藥性。這種方向的轉變迫使臨床負責人採用適應性強的方案和富含生物標記的隊列，以加速訊號檢測並最佳化資源配置。

近期美國關稅政策變化對生技藥品供應鏈、生產策略、臨床試驗連續性和商業合約動態的廣泛影響

美國關稅調整和貿易政策的演變將對生物腫瘤產品的臨床供應鏈、生產決策和商業策略產生連鎖反應。進口組件、成品生技藥品或專用耗材關稅的提高可能會促使製造商重新評估籌資策略，並透過調整某些生產流程的資源配置或深化與國內契約製造製造商的合作關係來減輕影響。此類變化將影響前置作業時間、資金配置以及灌裝和無菌生技藥品生產長期產能投資的優先順序。

從產品類別、腫瘤適應症、醫療環境、分銷管道、給藥途徑和企業策略等多個維度進行細緻的市場觀點，以挖掘差異化的商業機會。

對市場細分進行細緻分析，可以發現臨床效用和商業策略會因產品類型、適應症、最終用戶、分銷管道、給藥途徑和公司所有權的不同而有所差異。在產品類型內部，PD-1抑制劑和PD-L1抑制劑之間的差異在臨床和商業性仍然十分顯著。以cemipilimab、 Nivolumab和Pembrolizumab等藥物為代表的PD-1抑制劑，通常在多種腫瘤類型的單藥治療中具有持久療效，而以Atezolizumab、 Avelumab和Durvalumab等藥物為代表的PD-L1抑製劑則在特定適應症和聯合治療領域佔據戰略地位。這些治療模式層面的差異體現在研究設計、安全性管理和標靶產品特性等。

主要地區不同的監管環境、支付方期望和醫療服務體系如何驅動生技藥品的差異化准入策略和證據優先排序

美洲、歐洲、中東和非洲以及亞太地區的區域動態影響著藥物的可近性、臨床應用和戰略重點，每個地區都呈現出不同的法律規範、報銷文化和醫療服務模式。在美洲，先進的臨床試驗基礎設施和集中化的報銷機制促進了新適應症的早期應用和快速整合，而療效和成本效益指標則是相關人員談判的重點。歐洲、中東和非洲則呈現出由眾多國家監管機構和支付系統組成的複雜格局，這些機構和系統強調衛生技術評估和預算影響分析，要求製造商開發針對特定地區的證據包裝和患者准入計劃。

競爭對手層面的分析重點在於產品組合最佳化、組合策略、配方創新和經營能力，以支持在免疫腫瘤學領域的長期領先地位。

主要企業正在最佳化其產品組合，透過將臨床差異化與規模擴張相結合，以保持長期領先地位。阿斯特捷利康專注於策略併購和腫瘤學合作，以強化其適應症和互補資產，並利用其研發網路推出新型聯合檢測。百時美施貴寶則保持其廣泛的免疫腫瘤業務佈局，專注於透過聯合檢測和真實世界證據生成進行生命週期管理，以保持其在各個治療領域的臨床相關性。同時，羅氏正利用其診斷能力和深厚的腫瘤學專業知識，將伴隨檢測與治療方案的部署相結合。

製造商和相關人員的策略和營運重點在於提高生技藥品的可及性、推動臨床差異化以及增強供應和商業性韌性。

行業領導者應協調商業性、臨床和營運等多方面資源，以最大限度地提高患者用藥可及性，並在不斷發展的查核點抑制劑市場中保持競爭優勢。在策略層面，他們優先發展能夠產生生物標記驅動證據並證明組合方案具有疊加獲益的研發管道，以搶佔具有臨床意義的細分市場。同時，他們正加速投資於製劑創新，特別是皮下給藥和固定劑量複方製劑，以降低給藥複雜性，拓展門診治療模式，同時確保安全性和藥物動力學等效性。

採用透明的多方法研究途徑，結契約儕審查文獻、監管文件、專家訪談和資料三角驗證，以確保臨床和商業性有效性。

支持這份執行報告的研究採用了一種多方法整合策略，旨在對高品質證據和專家見解進行三角驗證。二手文獻和同行評審的臨床研究為作用機制解讀、安全性分析和臨床療效比較提供了科學依據，而監管文件和已發布的製劑資訊則提供了關於核准適應症和給藥策略的有效細節。主要研究包括對臨床研究人員、醫院藥劑師、支付方和行業高管進行結構化訪談，以了解未來在推廣應用障礙、報銷動態和營運限制方面的看法。

整合臨床、商業性和營運方面的必要因素，以確定如何將查核點抑制劑的科學進步轉化為永續、可近的癌症治療。

PD-1 和 PD-L1 抑制劑目前的進展軌跡標誌著該領域正處於戰略轉折點。科學進步和監管靈活性正在拓展治療的可能性，而商業和營運壓力正在重塑治療的交付方式。在這種環境下取得成功需要雙管齊下：一方面，透過生物標記主導的研發和合理的聯合用藥實現臨床差異化；另一方面，在生產、分銷和醫保支付方參與方面務實地執行。相關人員，將更有能力在應對經濟和政策逆風的同時，為病患帶來持續的益處。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新型雙特異性抗體標靶PD-1和其他免疫查核點，以克服抗藥性機制
  • PD-1/PD-L1抑制劑在早期癌症治療和輔助性治療的廣泛應用正在改善患者的存活預後。
  • 預測性生物標記和伴隨診斷技術的進步將最佳化PD-1/PD-L1療法的患者選擇
  • PD-1/PD-L1抑制劑、新型標靶治療和化療組合方案固體癌的療效已提高
  • 開發下一代PD-1/PD-L1抑制劑，其特點是安全性更高，臨床試驗中免疫相關不利事件更少
  • 透過擴大PD-1/PD-L1抑制劑在罕見癌症和非自體免疫疾病的適應症，增加患者獲得治療的機會。
  • 整合真實世界證據與衛生經濟學分析，為全球市場PD-1/PD-L1抑制劑的報銷決策提供支持

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. PD-1 和 PD-L1 抑制劑市場（依產品類型分類）

  • PD-1
    • 塞米匹利單抗
    • Nivolumab
    • Pembrolizumab
  • PD-L1抑制劑
    • Atezolizumab
    • Avelumab
    • Durvalumab

9. 依適應症分類的PD-1和PD-L1抑制劑市場

  • 膀胱癌
  • 頭頸癌
  • 肺癌
  • 黑色素瘤
  • 腎臟細胞癌

10. 按最終用戶分類的PD-1和PD-L1抑制劑市場

  • 醫院
  • 研究所
  • 專科診所

11. PD-1 和 PD-L1 抑制劑市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

12. 依給藥途徑分類的PD-1和PD-L1抑制劑市場

  • 靜脈注射
  • 皮下注射

13. 各公司PD-1及PD-L1抑制劑市場

  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck
  • Roche

14. 各地區PD-1及PD-L1抑制劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. PD-1 和 PD-L1 抑制劑市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國PD-1及PD-L1抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Merck KGaA
    • Pfizer Inc.
    • BeiGene, Ltd.
    • Innovent Biologics, Inc.
    • CStone Pharmaceuticals
    • Shanghai Junshi Biosciences Co., Ltd.
Product Code: MRR-4659C8713636

The PD-1 & PD-L1 Inhibitors Market is projected to grow by USD 208.06 billion at a CAGR of 21.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 44.61 billion
Estimated Year [2025] USD 53.91 billion
Forecast Year [2032] USD 208.06 billion
CAGR (%) 21.22%

A strategic primer on PD-1 and PD-L1 inhibitors that frames clinical maturation, competitive differentiation, and the systemic implications for oncology stakeholders

The field of immune checkpoint blockade has matured from proof-of-concept to a foundational pillar of modern oncology, driven primarily by therapies that target PD-1 and PD-L1. These agents have shifted paradigms in multiple tumor types by enabling durable responses in patient populations that previously had limited systemic options. As a result, stakeholders across biopharma, oncology practice, and policy are recalibrating portfolios, clinical pathways, and reimbursement approaches to reflect an era where immunomodulation is often central to combination regimens and long-term disease control.

Recent clinical and translational advances have expanded indications and refined patient selection strategies, elevating the importance of biomarkers, trial design, and real-world evidence to guide appropriate use. Simultaneously, competition among established biologic developers and newer entrants has accelerated innovation in formulation, dosing, and combination approaches. Investors and commercial leaders must parse differentiators such as novel administration routes, safety profiles that impact line of therapy, and strategic collaborations that extend lifecycle value. Consequently, this introduction frames the broader clinical and commercial context that underpins subsequent analysis, emphasizing the interplay between scientific progress and practical adoption in health systems.

How scientific combination strategies, regulatory flexibility, and commercial innovation are converging to redefine therapeutic trajectories for immune checkpoint therapies

The therapeutic landscape for PD-1 and PD-L1 inhibitors is undergoing transformative shifts driven by scientific, regulatory, and commercial forces that are converging to reshape standards of care. Mechanistically, the field is moving beyond monotherapy into rational combinations that pair checkpoint inhibitors with targeted agents, cytotoxic regimens, anti-angiogenics, and novel immunomodulators to broaden patient benefit and overcome resistance. These directional changes are prompting clinical trialists to adopt adaptive protocols and biomarker-enriched cohorts to accelerate signal detection and optimize resource allocation.

On the regulatory front, greater willingness to grant accelerated approvals in biomarker-defined populations has incentivized developers to pursue clear translational hypotheses and robust post-marketing evidence plans. Payers, in turn, are evolving reimbursement frameworks to reward value, including outcomes-based and indication-specific arrangements that recognize long-term benefits and manage upfront costs. Commercially, manufacturers are investing in differentiated formulations, such as subcutaneous preparations and fixed-dose regimens, to improve administration economics and patient convenience. Collectively, these shifts are driving consolidation in strategic partnerships, targeted M&A activity focused on complementary modalities, and increased emphasis on supply chain resilience to support broader global access.

The broad repercussions of recent United States tariff shifts on biologics supply chains, manufacturing strategies, clinical trial continuity, and commercial contracting dynamics

Tariff adjustments and trade policy developments in the United States create ripple effects across the clinical supply chain, manufacturing decisions, and commercial strategies for biologic oncology products. When duties increase on imported components, finished biologics, or specialized consumables, manufacturers reassess sourcing strategies, potentially reshoring certain manufacturing steps or deepening relationships with domestic contract manufacturers to mitigate exposure. These shifts have implications for lead times, capital allocation, and the prioritization of long-term capacity investments in fill-finish and sterile biologics manufacturing.

In the commercial arena, changes in import costs can influence list price negotiations, reimbursement discussions, and contracting terms with large health systems that emphasize cost predictability. Pharmaceutical companies often respond by optimizing distribution patterns, negotiating broader supplier agreements, and exploring formulation changes that reduce reliance on imported excipients or single-use systems. For clinical research, tighter cross-border supply constraints may slow initiation of global trials or require contingency stocks for investigational products, prompting greater use of regional hubs and enhanced inventory planning. Importantly, the combined effect of tariff changes encourages an industry-wide focus on supply chain visibility, diversified supplier ecosystems, and contractual protections that together preserve patient access and trial integrity.

A detailed segmentation perspective that interweaves product classes, tumor indications, care settings, distribution pathways, administration routes, and corporate strategies to illuminate differentiated opportunities

A nuanced examination of segmentation clarifies how clinical utility and commercial strategy vary across product type, indication, end users, distribution channels, route of administration, and corporate ownership. Within product type, distinctions between PD-1 inhibitors and PD-L1 inhibitors remain clinically and commercially salient; the PD-1 class, represented by agents such as cemiplimab, nivolumab, and pembrolizumab, often leads in monotherapy durability across multiple tumor types, whereas PD-L1 inhibitors including atezolizumab, avelumab, and durvalumab are strategically positioned in specific indications and combinatorial niches. These modality-level differences inform trial design, safety management, and target product profiles.

Indication stratification further refines opportunity sets: tumor types such as bladder cancer, head and neck cancer, lung cancer, melanoma, and renal cell carcinoma each present distinct response patterns, lines of therapy considerations, and biomarker dependencies that influence label strategy and adoption timing. From the end user perspective, hospitals, research institutes, and specialty clinics drive demand through differing procurement cycles, clinical expertise, and formulary governance, which in turn affects outreach, clinical education, and service model investments. Distribution channel analysis shows that hospital pharmacies, online pharmacies, and retail pharmacies each contribute to patient access pathways, with hospital-based administration remaining central for many intravenous regimens while alternative channels support transitions to outpatient care.

Route of administration divides opportunities between intravenous and subcutaneous approaches, with subcutaneous formulations increasingly attractive for lowering infusion center burden and improving patient convenience, subject to clinical equivalence and reimbursement alignment. Company-level segmentation highlights strategic positioning by major developers-AstraZeneca, Bristol-Myers Squibb, Merck & Co., and Roche-each leveraging distinct pipelines, combination agendas, and geographic footprints to defend and expand clinical indications. Integrating these segmentation lenses provides a granular view of where competitive pressure, clinical unmet need, and operational complexity intersect, guiding commercialization, clinical trial prioritization, and partnership decisions.

How divergent regulatory landscapes, payer expectations, and care delivery ecosystems across major regions drive differentiated access strategies and evidence priorities for oncology biologics

Regional dynamics shape access, clinical adoption, and strategic priorities across the Americas, Europe, the Middle East and Africa, and Asia-Pacific, with each geography presenting distinct regulatory frameworks, reimbursement cultures, and care delivery models. In the Americas, advanced clinical trial infrastructure and centralized reimbursement mechanisms in certain markets drive early adoption and rapid integration of new indications, while stakeholder negotiations focus on outcomes and cost-effectiveness metrics. Europe, the Middle East and Africa feature a mosaic of national regulatory bodies and payer systems that value health technology assessment and budget impact analyses, requiring manufacturers to craft localized evidence packages and patient access programs.

Asia-Pacific markets vary widely in capacity and policy stance, from highly developed systems with fast regulatory review pathways to emerging markets where access depends on tiered pricing, local manufacturing partnerships, and government procurement strategies. Cross-region collaboration on clinical development often accelerates indication expansion, but companies must navigate import controls, regional manufacturing requirements, and divergent standards for biomarker testing. Collectively, these regional factors influence launch sequencing, evidence generation priorities, and the design of commercial models that balance global platform capabilities with local execution needs.

Competitive company-level analysis focused on portfolio optimization, combination strategies, formulation innovation, and operational capabilities that underpin long-term leadership in immune-oncology

Leading companies in the PD-1 and PD-L1 domain are refining portfolios to sustain long-term leadership by combining clinical differentiation with operational scale. AstraZeneca has focused on strategic combinations and oncology partnerships to bolster indications and complementary assets, leveraging its development networks to test novel pairings. Bristol-Myers Squibb maintains a broad immuno-oncology footprint and emphasizes lifecycle management via combination trials and supportive real-world evidence generation to sustain clinical relevance across lines of therapy. Merck & Co. continues to prioritize robust biomarker strategies and global clinical operations to preserve first-mover advantages in several tumor types, while Roche leverages diagnostic capabilities and deep oncology expertise to align companion testing with therapeutic deployment.

Across the competitive set, companies are advancing strategies such as developing subcutaneous formulations to reduce infusion burden, pursuing label expansions through combination regimens, and securing supply chain resilience via diversified manufacturing. Partnerships with biotech innovators and investments in digital health to support patient management and adherence are increasingly important differentiators. Intellectual property fences, regulatory commitments, and post-approval evidence plans all shape how these firms defend market positions and create new value in an environment where clinical nuance and operational excellence determine whether a therapy becomes a long-term standard component of oncologic care.

Actionable strategic and operational priorities for manufacturers and stakeholders to enhance access, drive clinical differentiation, and fortify supply and commercial resilience in oncology biologics

Industry leaders should align commercial, clinical, and operational levers to maximize patient access and sustain competitive advantage in the evolving checkpoint inhibitor landscape. Strategically, prioritize development pathways that generate biomarker-driven evidence and demonstrate additive benefit in combination regimens to capture clinically meaningful niches. Concurrently, accelerate investments in formulation innovation, particularly subcutaneous and fixed-dose options, to reduce administration complexity and expand outpatient treatment models, while ensuring comparative safety and pharmacokinetic equivalence.

Operationally, enhance supply chain resilience by diversifying suppliers, securing regional manufacturing capacity where feasible, and embedding scenario planning for trade policy shifts that may affect component availability. On the commercial front, engage early with payers and health technology assessment bodies to co-develop value frameworks and consider indication-specific contracting models that align price with demonstrated outcomes. Clinically, expand real-world evidence programs and registries to support long-term effectiveness and safety narratives, and leverage digital tools to improve patient identification, adherence, and survivorship care. Finally, pursue targeted partnerships and licensing arrangements with smaller innovators to access complementary modalities while managing capital allocations and regulatory risk.

A transparent multi-method research approach combining peer-reviewed literature, regulatory documents, expert interviews, and data triangulation to ensure clinical and commercial validity

The research underpinning this executive synthesis integrates a multi-method approach designed to triangulate high-quality evidence and expert insight. Secondary literature and peer-reviewed clinical studies provided the scientific foundation for mechanism-of-action interpretation, safety profiles, and comparative clinical outcomes, while regulatory filings and published prescribing information offered validated detail on approved indications and dosing strategies. Primary research included structured interviews with clinical investigators, hospital pharmacists, payers, and industry executives to capture forward-looking perspectives on adoption barriers, reimbursement dynamics, and operational constraints.

Data triangulation ensured alignment among disparate information streams, with a rigorous validation process that cross-checked clinical claims against trial registries and regulatory documents. The methodology emphasized transparency in assumptions and source citation, and the synthesis underwent peer review by therapeutic-area experts to ensure clinical accuracy and relevance. Where possible, real-world evidence and registry data were used to corroborate trial observations, and sensitivity checks addressed potential bias from selective reporting. This layered methodology balances depth of clinical insight with practical commercial intelligence to support informed decision-making.

Synthesis of clinical, commercial, and operational imperatives that will determine how checkpoint inhibitors translate scientific progress into durable, accessible cancer care

The current trajectory of PD-1 and PD-L1 inhibitors demonstrates a field in strategic transition: scientific advances and regulatory flexibility are expanding therapeutic potential, while commercial and operational pressures are reshaping how therapies reach patients. Success in this environment requires a dual focus on clinical differentiation-through biomarker-led development and rational combinations-and on pragmatic execution around manufacturing, distribution, and payer engagement. Stakeholders that balance innovation with operational rigor will be best positioned to deliver sustained patient benefit while navigating economic and policy headwinds.

Looking ahead, continued investment in translational science, adaptive trial designs, and real-world evidence generation will be critical to unlock new indications and optimize patient selection. At the same time, companies must proactively manage supply chain and pricing risks, engage with regional stakeholders to tailor access strategies, and pursue partnerships that accelerate complementary capabilities. In sum, the future of checkpoint inhibition will be determined not only by clinical breakthroughs but by the industry's ability to translate those breakthroughs into accessible, cost-effective care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging bispecific antibodies targeting PD-1 and additional immune checkpoints to overcome resistance mechanisms
  • 5.2. Increasing adoption of PD-1/PD-L1 inhibitors in earlier cancer treatment lines and adjuvant therapy settings to improve patient survival outcomes
  • 5.3. Advancements in predictive biomarkers and companion diagnostics to optimize patient selection for PD-1/PD-L1 therapies
  • 5.4. Combination regimens involving PD-1/PD-L1 inhibitors with novel targeted therapies and chemotherapy in solid tumors to enhance efficacy
  • 5.5. Development of next generation PD-1/PD-L1 inhibitors featuring improved safety profiles and reduced immune-related adverse events in clinical trials
  • 5.6. Expanding therapeutic indications for PD-1/PD-L1 inhibitors in rare cancers and non-oncology autoimmune conditions to broaden patient access
  • 5.7. Integration of real-world evidence and health economic analyses to support reimbursement decisions for PD-1/PD-L1 inhibitors across global markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PD-1 & PD-L1 Inhibitors Market, by Product Type

  • 8.1. PD-1 Inhibitor
    • 8.1.1. Cemiplimab
    • 8.1.2. Nivolumab
    • 8.1.3. Pembrolizumab
  • 8.2. PD-L1 Inhibitor
    • 8.2.1. Atezolizumab
    • 8.2.2. Avelumab
    • 8.2.3. Durvalumab

9. PD-1 & PD-L1 Inhibitors Market, by Indication

  • 9.1. Bladder Cancer
  • 9.2. Head And Neck Cancer
  • 9.3. Lung Cancer
  • 9.4. Melanoma
  • 9.5. Renal Cell Carcinoma

10. PD-1 & PD-L1 Inhibitors Market, by End User

  • 10.1. Hospitals
  • 10.2. Research Institutes
  • 10.3. Specialty Clinics

11. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. PD-1 & PD-L1 Inhibitors Market, by Route Of Administration

  • 12.1. Intravenous
  • 12.2. Subcutaneous

13. PD-1 & PD-L1 Inhibitors Market, by Company

  • 13.1. AstraZeneca
  • 13.2. Bristol-Myers Squibb
  • 13.3. Merck & Co.
  • 13.4. Roche

14. PD-1 & PD-L1 Inhibitors Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. PD-1 & PD-L1 Inhibitors Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. PD-1 & PD-L1 Inhibitors Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Merck & Co., Inc.
    • 17.3.2. Bristol-Myers Squibb Company
    • 17.3.3. F. Hoffmann-La Roche Ltd
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. Merck KGaA
    • 17.3.6. Pfizer Inc.
    • 17.3.7. BeiGene, Ltd.
    • 17.3.8. Innovent Biologics, Inc.
    • 17.3.9. CStone Pharmaceuticals
    • 17.3.10. Shanghai Junshi Biosciences Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLI